Abstract
The results of the whole-exome DNA sequencing of eight prostate adenocarcinoma patients are presented. DNA was isolated from the peripheral blood as well as healthy and tumor prostate tissue from each patient. Bioinformatics analysis was conducted and the most significant mutations in prostate cancer patients were revealed. The obtained data could be important for understanding of the molecular mechanisms of prostate cancer pathogenesis and facilitate development of new approaches for treatment of the disease.
References
Kaprin, A.D., Starinskii, V.V., and Petrova, G.V., Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost’ i smertnost’) (Malignancies in Russia in 2013 (Morbidity and Mortality)), Moscow: Mosk. Nauchno-Issled. Onkol. Inst. im. P.A. Gertsena, 2015.
Taylor, B.S., Schultz, N., Hieronymus, H., et al., Integrative genomic profiling of human prostate cancer, Cancer Cell, 2010, vol. 18, no. 1 pp. 11–22. doi 10.1016.j.ccr.2010.05.026
Tomlins, S.A., Bjartell, A., Chinnaiyan, A.M., et al., ETS gene fusions in prostate cancer: from discovery to daily clinical practice, Eur. Urol., 2009, vol. 56, no. 2 pp. 275–286. doi 10.1016/j.eururo.2009.04.036
He, W.W., Sciavolino, P.J., Wing, J., et al., A novel human prostate-specific, androgen-regulated homeobox gene (NKX3. 1) that maps to 8p21, a region frequently deleted in prostate cancer, Genomics, 1997, vol. 43, no. 1 pp. 69–77. doi 10.1006/geno.1997.4715
Lapointe, J., Li, C., Giacomini, C.P., et al., Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis, Cancer Res., 2007, vol. 67, pp. 8504–8510. doi 10.1158/0008-5472.CAN-07-0673
Thangapazham, R., Saenz, F., Katta, S., et al., Loss of the NKX3.1 tumor suppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer, BMC Cancer, 2014, vol. 14, pp. 16. doi 10.1186/1471-2407-14-16
Barbieri, C.E., Baca, S.C., Lawrence, M.S., et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat. Genet., 2012, vol. 44, no. 6 pp. 685–689. doi 10.1038/ng.2279
Li, H. and Durbin, R., Fast and accurate short read alignment with Burrows—Wheeler transform, Bioinformatics, 2009, vol. 25, no. 14 pp. 1754–1760. doi 10.1093/bioinformatics/btp324
DePristo, M.A., Banks, E., Poplin, R., et al., A framework for variation discovery and genotyping using nextgeneration DNA sequencing data, Nat. Genet., 2011, vol. 43, no. 5 pp. 491–498. doi 10.1038/ng.806
Yang, H. and Wang, K., Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR, Nat. Protoc., 2015, vol. 10, no. 10 pp. 1556–1566. doi 10.1038/nprot.2015.105
Kircher, M., Witten, D.M., Jain, P., et al., A general framework for estimating the relative pathogenicity of human genetic variants, Nat. Genet., 2014, vol. 46, no. 3 pp. 310–315. doi 10.1038/ng.2892
Karolczak-Bayatti, M., Loughney, A.D., Robson, S.C., and Europe-Finner, G.N., Epigenetic modulation of the protein kinase A RIIa (PRKAR2A) gene by histone deacetylases 1 and 2 in human smooth muscle cells, J. Cell. Mol. Med., 2011, vol. 15, no. 1 pp. 94–108. 00927.x doi 10.1111/j.1582-4934.2009
Chernogubova, E.A., Braslavskaya, I.V., and Golikov, A.Yu., The role of serine proteases in the pathogenesis of prostate cancer, Vestn. Yuzhn. Nauchn. Tsentra Ross. Akad. Nauk, 2009, vol. 5, no. 1 pp. 81–93.
Chugh, S., Gnanapragassam, V.S., Jain, M., et al., Pathobiological implications of mucin glycans in cancer: sweet poison and novel targets, Biochim. Biophys. Acta, Rev. Cancer, 2015, vol. 1856, no. 2, pp. 211–225.
Haridas, D., Chakraborty, S., Ponnusamy, M.P., et al., Pathobiological implications of MUC16 expression in pancreatic cancer, PLoS One, 2011, vol. 6, no. 10. e26839.
Lakshmanan, I., Ponnusamy, M.P., Das, S., et al., MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and antiapoptosis in breast cancer cells, Oncogene, 2012, vol. 31, no. 7 pp. 805–817.
Chen, S.H., Hung, W.C., Wang, P., et al., Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation, Sci. Rep., 2013, vol. 3, p. 1870.
Turner, D., Findlay, V., Darby Kirven, A., tet al., Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression, {iMol. Biol. Cell}, 2008, vol. 19(9), pp. 3745–3757.
Grasso, C.S., Wu, Y.M., Robinson, D.R., et al., The mutational landscape of lethal castration-resistant prostate cancer, Nature, 2012, vol. 487, no. 7406 pp. 239–243.
Lindberg, J., Mills, I.G., Klevebring, D., et al., The mitochondrial and autosomal mutation landscapes of prostate cancer, Eur. Urol., 2013, vol. 63, no. 4 pp. 702–708.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © I.R. Gilyazova, M.A. Yankina, G.B. Kunsbaeva, E.A. Klimentova, A.A. Izmaylov, V.N. Pavlov, E.K. Khusnutdinova, 2016, published in Genetika, 2016, Vol. 52, No. 9, pp. 1103–1108.
Rights and permissions
About this article
Cite this article
Gilyazova, I.R., Yankina, M.A., Kunsbaeva, G.B. et al. Mutational landscape of prostate tumors revealed by whole-exome sequencing. Russ J Genet 52, 999–1003 (2016). https://doi.org/10.1134/S1022795416090052
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1022795416090052